
PF-06447475
CAS No. 1527473-33-1
PF-06447475( PF06447475 )
Catalog No. M12138 CAS No. 1527473-33-1
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 of 3 and 11nM for WT LRRK2 and G2019S mutant, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 39 | In Stock |
![]() ![]() |
10MG | 55 | In Stock |
![]() ![]() |
25MG | 80 | In Stock |
![]() ![]() |
50MG | 120 | In Stock |
![]() ![]() |
100MG | 203 | In Stock |
![]() ![]() |
200MG | 357 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePF-06447475
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 of 3 and 11nM for WT LRRK2 and G2019S mutant, respectively.
-
DescriptionPF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 of 3 and 11nM for WT LRRK2 and G2019S mutant, respectively; PF-06447475 is also sufficiently potent in the LRRK2 whole cell assay with IC50 of 25 nM; protects nerve-like differentiated cells (NLCs) against rotenone induced noxious effect, prevents α-synuclein-induced neurodegeneration in rats.
-
In VitroPF-06447475 inhibits LRRK2 enzyme and LRRK2 in the whole cell assay with IC50s of 3 and 25 nM, respectively. Cells incubated with PF-06447475 alone (0.5, 1, 3 μM) or in the presence of ROT significantly reduces (S935)-LRRK2 kinase phosphorylation to control. PF-06447475 significantly preserves the nucleus morphology and ΔΨm of NLCs exposed to ROT compared to untreated and control. PF-475 significantly diminishes ROT-induced ROS generation to a similar extent to cells exposed to PF-475 alone.
-
In VivoIn G2019S+ rats treated with PF-06447475, a significant reduction in microgliosis to levels found in wild-type rats could be observed. The proinflammatory marker MHC-II expressed on myeloid cells but not neurons also appears to be less abundant in confocal sections in G2019S+ rats treated with PF-06447475. PF-06447475 treatment in G2019S+ rats significantly lowers the number of CD68 cells recruited to the SNpc. PF-06447475 successfully blocks the enhanced neuroinflammation associated with G2019S-LRRK2 expression. Treatment of G2019S+ rats with PF-06447475 preserves TH expression in the dorsal striatum, consistent with drug attenuating neurodegeneration in the SNpc. PF-06447475 is well tolerated in rats.
-
SynonymsPF06447475
-
PathwayAutophagy
-
TargetLRRK2
-
RecptorG2019SLRRK2|LRRK2
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number1527473-33-1
-
Formula Weight305.3339
-
Molecular FormulaC17H15N5O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESN#CC1=CC=CC(C2=CNC3=NC=NC(N4CCOCC4)=C32)=C1
-
Chemical NameBenzonitrile, 3-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Henderson JL, et al. J Med Chem. 2015 Jan 8;58(1):419-32.
2. Daher JP, et al. J Biol Chem. 2015 Aug 7;290(32):19433-44.
3. Mendivil-Perez M, et al. Neurochem Res. 2016 Oct;41(10):2675-2692.
4. Volpicelli-Daley LA, et al. J Neurosci. 2016 Jul 13;36(28):7415-27.
molnova catalog



related products
-
GSK2578215A
GSK2578215A is a highly potent, selective, BBB-permeable LRRK2 inhibitor with IC50 of 10.9 and 9.9 nM for wild-type LRRK2 and the G2019S mutant, respectively.
-
CZC-25146 hydrochlor...
CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
-
CZC-54252 hydrochlor...
CZC-54252 hydrochloride is a selective inhibitor of LRRK2 with IC50s of 1.85 nM and 1.28 nM for wild-type and G2019S LRRK2.